Of particular importance, the differential expression of LGMN observed between these subtypes implies its potential as a biomarker for subgroup differentiation, thereby furnishing a robust molecular basis for the implementation of personalized medicine strategies in osteosarcoma. This evidence concerns the gene LGMN and osteosarcoma.